Management Team

Bradford J. Duft

Co-Founder, President, CEO and Director

Before co-founding CoDa Therapeutics, Mr. Duft was a partner in the law firm Duane Morris. From 1990 through 1998, Mr. Duft was Senior Vice President and General Counsel of Amylin Pharmaceuticals. His 25 year legal practice has focused on biotechnology company strategy and growth, with an emphasis on intellectual property licensing, strategic patent prosecution, and litigation. In addition to experience in crafting and building U.S. and worldwide patent portfolios, Mr. Duft has drafted and negotiated numerous biotechnology agreements, including local and worldwide joint research agreements, joint development agreements and corporate partnership agreements, as well as numerous licenses.

Mr. Duft is a graduate of the George Washington University Law School, where he received a Masters in Patent and Trade Regulation, (LL.M., with highest honors), the California Western School of Law (J.D., cum laude), and the University of Colorado where he received his degree in Molecular, Cellular and Developmental Biology.

Tracey Sunderland

Chief Operating Officer

Ms. Sunderland oversees the integration and execution of CoDa Therapeutics' operating strategy, including advancing all of its preclinical, clinical and regulatory programs. She has direct responsibility in technical operations, business development, and high performance strategic planning efforts for the organization, including overall project planning, scheduling, and resource allocation. Ms. Sunderland has been with the company since operations began following initial financing in October 2006, serving most recently as Manager of New Zealand Operations.

Prior to joining CoDa Ms. Sunderland was with Protemix Corporation for 5 years. Before that she had appointments at LabPlus, Auckland Healthcare, and Greenlane/National Women's Hospital. Ms. Sunderland received her degree in Medical Laboratory Science from the Auckland University of Technology, where she majored in clinical biochemistry.

David Pool

Chief Financial Officer

Mr. Pool joined CoDa Therapeutics as Chief Financial Officer in July 2008. He has over 20 years investment banking and venture capital experience including privatization transactions, leasing, securitizations, venture capital raising and initial public offerings. Mr. Pool has raised over $50M for early stage Biotech companies. Mr. Pool's responsibilities include all financial and accounting functions as well as driving CoDa's fund raising process and business development activities.

Prior to CoDa, Mr. Pool was Protemix Corporation's Chief Operating and Financial Officer for 5 years. Mr. Pool holds a Bachelor of Commerce in accounting and business administration from the University of Canterbury and is a member of the Institute of Chartered Accountants of New Zealand.


Dr. David E. Eisenbud, M.D.

Chief Medical Officer

Dr. Eisenbud has over 20 years of experience as a vascular surgeon with particular expertise in wound evaluation and management.  In addition to his role as Medical Director of the Overlook Hospital Wound Healing Program in Summit, NJ, Dr. Eisenbud is also Managing Partner at Millburn Surgical Associates (Millburn, NJ), a multi-physician group performing general and vascular surgery, non-invasive vascular laboratory evaluations, and wound care. Founder of Advanced BioHealing, Inc., a medical device firm commercializing cell-based wound healing therapies, Dr. Eisenbud has designed, managed, served as principal investigator, and/or reported to FDA many wound-healing clinical trials.  Dr. Eisenbud earned his B.S. (Chemistry, 1976); M.S. (Chemistry, 1979); M.D. (1981); and M.B.A. (1997) degrees from Yale University, the University of Chicago, the Pritzker School of Medicine, and New York University Stern School of Business, respectively.

Grove Matsuoka

Vice President - Commercialization

Mr. Matsuoka joined CoDa Therapeutics in November 2007 as Vice President Commercialization. Mr. Matsuoka brings his 20 years of drug development experience across Research & Development as well as Sales & Marketing to assist CoDa Therapeutics in commercializing novel wound healing therapeutics.

Prior to CoDa, Mr. Matsuoka led a Strategic Planning and Operations Group within Amgen's Medical Affairs Function and was Head of Amgen's Development Project Management Department for a number of years. While at Sandoz Pharmaceuticals (Novartis) and Immulogic Corporation, he obtained increasing commercial responsibilities in Field Sales and Product Management. Mr. Matsuoka received his MBA from Boston College and his Bachelor's Degree in Microbiology and Immunology from University of California at Berkeley.

Anthony Phillips, B.Sc, MB ChB, Ph.D

Medical Director

Dr. Phillips is CoDa Therapeutics' Medical Director where he is responsible for both preclinical and clinical development, strategy and execution. In addition to serving as Medical Director of CoDa, Dr. Phillips is a Senior Lecturer for the School of Biological Sciences, University of Auckland; a Transplant Surgical Fellow for the Liver Transplant Unit, Auckland City Hospital; and Laboratory Research Manager for the Pancreas Research Group, Auckland City Hospital.

Dr. Phillips previous industry positions were with Protemix Corporation as a Senior Scientist (Physiology - Group Leader) for five years. He has held research appointments at the Royal Australasian College of Surgeon's Research Fellowship and a HRC Training Fellowship. His clinical appointments include Liver Transplant Assistant, Auckland City Hospital; NZ Urology Registrar, Auckland City Hospital; NZ and General Surgical Registrar; Middlemore Hospital. Other previous clinical appointments include Surgical Registrar positions, North Shore Hospital and Hastings Memorial Hospital; Plastic Surgical Registrar, Middlemore Hospital; NZ and House Surgeon at Palmerston North Hospital, NZ.